首都医科大学附属北京朝阳医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma8 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma18 篇牵头论文
- 胃癌Stomach cancer12 篇牵头论文
- 脊索瘤Chordoma2 篇牵头论文
- 骨肉瘤Osteosarcoma6 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
- 神经母细胞瘤Neuroblastoma1 篇牵头论文
- 尤文肉瘤Ewing sarcoma2 篇牵头论文
- 多发性骨髓瘤Multiple myeloma52 篇牵头论文
- β 地中海贫血Beta thalassaemia0 篇牵头论文
- 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome0 篇牵头论文
- 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura0 篇牵头论文
- 大动脉炎Takayasu arteritis3 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis12 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
- 白塞病Behçet disease1 篇牵头论文
- IgA 肾病IgA nephropathy4 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis3 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis2 篇牵头论文
- 先天性膈疝Congenital diaphragmatic hernia1 篇牵头论文
- 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文
未列出的收录疾病:鼻咽癌、肝母细胞瘤、视网膜母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、血友病 A、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 13 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
牵头的论文8
- p53 and Ki-67 combined with periodic acid-Schiff staining for the diagnosis of early stage esophageal squamous cell carcinoma lesions in biopsy specimens.
- Phospholipase PLCE1 Promotes Transcription and Phosphorylation of MCM7 to Drive Tumor Progression in Esophageal Cancer.
- Expression and correlation of PD-L1 and HER2 in oesophageal squamous cell carcinoma.
- Correlation of PD-L1 expression with CD8+ T cells and oxidative stress-related molecules NRF2 and NQO1 in esophageal squamous cell carcinoma.
- Preventive Treatment with PD-1 Antibody Increases Tissue-resident Memory T Cells Infiltration and Delays Esophageal Carcinogenesis.
- APOC1 predicts a worse prognosis for esophageal squamous cell carcinoma and is associated with tumor immune infiltration during tumorigenesis.
- High expression of nuclear NRF2 combined with NFE2L2 alterations predicts poor prognosis in esophageal squamous cell carcinoma patients.
- DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway.
PubMed 以外找到的论文(未计入)12
- 193P DCLK1’s kinase activity drives its pro-stemness effect in esophageal squamous cell carcinoma
- Data from DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway
- Supplementary Figure 4 from DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway
- Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- RETRACTED ARTICLE: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling
- Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 18 篇,占 0.1%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 17 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。
这些数字背后的记录
牵头的论文18
- Integrated analysis and experimental validation reveal the prognostic and immunological features associated with coagulation in hepatocellular carcinoma.
- LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy.
- Impact of metabolic dysfunction-associated fatty liver disease on liver transplant recipients with hepatitis B virus-related hepatocellular carcinoma.
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma.
- Anti-PD-1 therapy reverses TIGIT+CD226+NK depletion in immunotherapy resistance of hepatocellular carcinoma through PVR/TIGIT pathway.
- Metformin promotes the normalization of abnormal blood vessels after radiofrequency ablation deficiency in hepatocellular carcinoma by microRNA-302b-3p targeting thioredoxin-interacting protein.
- Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.
- Therapeutically targeting essential metabolites to improve immunometabolism manipulation after liver transplantation for hepatocellular carcinoma.
- Preoperative systemic inflammatory response index predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation.
- Unveiling the Mystery of SUMO-activating enzyme subunit 1: A Groundbreaking Biomarker in the Early Detection and Advancement of Hepatocellular Carcinoma.
- Prognosis of Liver Transplantation for Hepatocellular Carcinoma in Terms of Different Criteria: A Single Center Experience.
- Anatomic resection versus radiofrequency ablation with an ablative margin ≥ 1.0 cm for solitary small hepatocellular carcinoma measuring ≤ 3 cm: Comparison of long-term outcomes using propensity score matching analysis.
- Safety and efficacy of microwave versus radiofrequency ablation for large hepatic hemangioma: a multicenter retrospective study with propensity score matching.
- Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2.
- Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1α-mediated glycolysis in hepatocellular carcinoma.
- Intrahepatic hemorrhage and recurrence caused by arterioportal fistula after radiofrequency ablation for hepatocellular carcinoma: A thought-provoking ablation-related complication.
- The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation.
- PD-L1+NEUT, Foxp3+Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 15 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- 分期
- 未注明
- 开始
- 2025-02
- 登记号
- NCT06846996
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文12
- Lipidomic machine learning predictor for progression of gastric cancer.
- Clinicopathological features and mucin expression of early papillary gastric adenocarcinoma.
- Diagnostic Value of Joint Detection of Serum TK1, TSGF, CA199, and CA724 for Gastric Cancer and Its Relationship With Clinicopathologic Features and Prognosis.
- GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration.
- Gastric Cancer Immune Subtypes and Prognostic Modeling: Insights from Aging-Related Gene Analysis.
- Advanced Gastric Cancer: CT Radiomics Prediction of Lymph Modes Metastasis After Neoadjuvant Chemotherapy.
- DNA methylation profiling identifies epigenetic signatures of early gastric cancer.
- Multimodality Therapy, Followed by Laparoscopic Gastrectomy, for Unresectable Gastric Cancer With Outlet Obstruction and Bulky N2 Metastases.
- Clinicopathological and molecular characteristics of the alpha-fetoprotein-producing gastric cancer: emphasis on two major subtypes.
- Deep learning for automatic diagnosis of gastric dysplasia using whole-slide histopathology images in endoscopic specimens.
- Silencing of ER-resident oxidoreductase PDIA3 inhibits malignant biological behaviors of multidrug-resistant gastric cancer.
- Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
中文论文(未计入)6
- [Neuroendocrine carcinoma with significantly vacuolar nucleus at the esophagogastric junction: A case report].
- [Clinicopathological features of Helicobacter pylori-negative early gastric cancer].
- [The value of Alcian blue periodic acid Schiff staining and Ki-67 expression in diagnosing gastric reactive epithelial hyperplasia and dysplasia].
- [Clinicopathological features of early gastric cancer after Helicobacter pylori eradication].
- [Clinicopathological features of very well-differentiated adenocarcinoma of the stomach].
- [Application and Progress of Convolutional Neural Network-based Pathological Diagnosis of Gastric Cancer].
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- Incidence of Pancreatic Fistula After Radical Gastrectomy
癌症
脊索瘤
Chordoma2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 11 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 48 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文6
- miR-486-3p Suppresses Osteosarcoma Proliferation and Migration by Targeting the SPRED1-MAPK/ERK Pathway.
- Research progress on cancer-associated fibroblasts in osteosarcoma.
- Clinicopathological and molecular genetic analysis of 13 cases of primary retroperitoneal Ewing sarcoma.
- Prognostic Signature in Osteosarcoma Based on Amino Acid Metabolism-Associated Genes.
- 18F-FDG PET/CT of Primary Extraskeletal Ewing Sarcoma of the Prostate.
- LncRNA LINC00958 promotes tumor progression through miR-4306/CEMIP axis in osteosarcoma.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 23 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 24 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 17 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)1
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 52 篇,占 3.1%。
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 15 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 14
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- 分期
- I期
- 开始
- 2026-05
- 登记号
- NCT07477587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛
- 正在招募A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- 分期
- III期
- 开始
- 2026-05
- 登记号
- NCT07518186
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、温州、西安、长春
- 正在招募Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
- 分期
- I期
- 开始
- 2026-03
- 登记号
- NCT07529782
年龄 未注明 至 18 岁(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、杭州、济南、苏州
- 正在招募Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
- 分期
- I期
- 开始
- 2026-09
- 登记号
- NCT07620275
年龄 18 岁 至 75 岁(登记的条件)
牵头:中国人民解放军总医院;另有 2 家列出的医院为研究中心北京、天津
- 正在招募A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- 分期
- III期
- 开始
- 2025-12
- 登记号
- NCT07297329
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
- 正在招募Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- 分期
- I期
- 开始
- 2024-05
- 登记号
- NCT06375044
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、南京、天津、广州、杭州、福州、郑州
- 正在招募A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- 分期
- III期
- 开始
- 2024-06
- 登记号
- NCT06508983
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、天津、广州、杭州、武汉、苏州、西安、郑州
- 正在招募A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
- 分期
- I期
- 开始
- 2024-06
- 登记号
- NCT06574568
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、哈尔滨、太原、广州、杭州、济南、郑州
- 正在招募Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
- 分期
- I/II期
- 开始
- 2023-02
- 登记号
- NCT05565807
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、杭州
- 正在招募Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- 分期
- III期
- 开始
- 2022-09
- 登记号
- NCT05243797
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、杭州、武汉、沈阳、济南、温州、郑州、长春
- 正在招募A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- 分期
- III期
- 开始
- 2022-10
- 登记号
- NCT05552222
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙
- 正在招募A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- 分期
- I/II期
- 开始
- 2021-09
- 登记号
- NCT04973605
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛
- 即将招募Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
- 分期
- II期
- 开始
- 2027-12
- 登记号
- NCT07695740
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
- 即将招募Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- 分期
- III期
- 开始
- 2026-06
- 登记号
- NCT07569757
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文52
- Prognostic Implications of Measurable Residual Disease and Autologous Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia in the Era of Novel Agents.
- The prognostic impact of 1q21 gain/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China.
- Temporal trends and disparities in cardiovascular disease-related mortality among adults with multiple myeloma in the United States, 1999-2023.
- Prognostic value of the expression of CD27 and CD117 in newly diagnosed multiple myeloma patients.
- Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi-Center, Open-Label Phase I Trial.
- Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: a retrospective cohort study.
- Exploring multiple myeloma pathobiology and immune cell signatures: Evidence from bidirectional genetic analysis.
- Analysis of clinical characteristics, treatment response, and prognosis among 67 patients with anaplastic multiple myeloma.
- Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study.
- Prognostic value of 18F-FDG PET/CT in patients with relapsed multiple myeloma.
- Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.
- Myeloma extracellular vesicle-derived RAGE increases inflammatory responses and myotube atrophy in multiple myeloma through activation of the TLR4/NF-κB p65 pathway.
- Evaluation of the Prognostic Value of the Mayo Additive Staging System and Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients.
- Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.
- KIAA1429 increases FOXM1 expression through YTHDF1-mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma.
- Detection of lenalidomide metabolites in urine to discover drug-resistant compounds.
- Proteomics analysis of serum and urine identifies VCP and CTSA as potential biomarkers associated with multiple myeloma.
- Bone marrow fibrosis in newly diagnosed multiple myeloma and its correlation with clinicopathological factors.
- Analysis of the efficacy of separation surgery for severe neurological compression in multiple myeloma: a retrospective analysis of 35 cases.
- Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma.
- Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center.
- Synchronous multiple myeloma and lung adenocarcinoma: A clinical series.
- Chromosome 1q21 Aberrations Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients.
- Wound healing after surgical therapy for multiple myeloma: a case-control study.
- Which factors are associated with adverse prognosis in multiple myeloma patients after surgery? - preliminary establishment and validation of the nomogram.
- The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma.
- Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.
- Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.
- Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era.
- Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients.
- In vivo antitumor efficacy of 17-AAG loaded PMMA in a human multiple myeloma xenograft mouse model.
- Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era.
- Biological research on the occurrence and development of multiple myeloma and its treatment.
- The effects of nutritional support on cellular immunity of the patient with multiple myeloma undergoing chemotherapy.
- Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.
- Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation.
- Incidence of multiple myeloma in Kailuan cohort: A prospective community-based study in China.
- Echocardiography-defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients.
- Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study.
- Routine blood biomarkers for the detection of multiple myeloma using machine learning.
- The Association Between Low T3 Syndrome and Survival in Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study.
- Pleural effusion-based nomogram to predict outcomes in unselected patients with multiple myeloma: a large single center experience.
- The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.
- Autologous peripheral blood stem cell transplantation as front-line therapy for myeloma with double-hit and triple-hit in a real-world study.
- Promoting effects of MiR-135b on human multiple myeloma cells via regulation of the Wnt/β-catenin/Versican signaling pathway.
- The Prevalence of Euthyroid Hypertriiodothyroninemia in Newly Diagnosed Multiple Myeloma and its Clinical Characteristics.
- A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
- Deep Learning-Based CT Imaging in Diagnosing Myeloma and Its Prognosis Evaluation.
- At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.
- Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.
- LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN.
- Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma.
中文论文(未计入)20
- [The Influence of COVID-19 Infection on the Mobilization and Collection of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma].
- [Clinical Analysis of Listeriosis in Treatment of Multiple Myeloma with Novel Agents].
- [Analysis of the efficacy of a carfilzomib-based regimen in the treatment of relapsed and refractory multiple myeloma].
- [Advances for treatment of relapsed or refractory multiple myeloma: interpretation of guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].
- [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].
- [Prognostic analysis of 19 newly treated multiple myeloma patients with t(14; 16)].
- [Analysis of the prognostic factors in primary plasma cell leukemia in the era of novel agents].
- [Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in the mobilization of autologous peripheral blood stem cells in patients with multiple myeloma].
- [Minimal residual disease assessment and progress in multiple myeloma].
- [MiR-203a-5p Inhibits Multiple Myeloma Cell Proliferation and Cell Cycle Progression via Targeting JAG1].
- [Application and significance of peripheral blood circulating plasma cells in the diagnosis of multiple myeloma].
- [Prognostic significance of immunoparesis in newly diagnosed multiple myeloma patients who achieved deep response].
- [Interpretation of treatment of relapsed/refractory multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China(2022 revision)].
- [The prognostic relationship between CD56 expression and newly diagnosed multiple myeloma].
- [Clinical analysis of 25 patients with non transplanted multiple myeloma who survived for more than 10 years].
- [MAS-like lesions and SIADH caused by bortezomib in the treatment of multiple myeloma : three cases report and literature review].
- [The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era].
- [Controversies on the diagnosis and treatment of relapsed/refractory multiple myeloma].
- [Clinical Analysis of 25 Non-Transplanted Multiple Myeloma Patients Treated with Bortezomib Maintenance].
- [Autologous stem cell transplantation improve the survival of newly diagnosed multiple myeloma patients].
它在 ClinicalTrials.gov 上的全部试验(任何状态)45
- Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics
- CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma
- Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients
- Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients
- Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
- Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
- Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- A Study of Daratumumab
- A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
- SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
- A Study of NINLARO® in Chinese Adults With Multiple Myeloma
- A Study of TQB3820 in Patients With Hematological Malignancies
- Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
- Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Ninlaro in Real World Clinical Practice in China
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
- TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
- A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
- Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
血液疾病
β 地中海贫血
Beta thalassaemia2021–2025 年没有牵头β 地中海贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 10 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。
血液疾病
非典型溶血性尿毒症综合征
Atypical haemolytic uraemic syndrome2021–2025 年没有牵头非典型溶血性尿毒症综合征的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 6 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。
这些数字背后的记录
血液疾病
血栓性血小板减少性紫癜
Thrombotic thrombocytopenic purpura2021–2025 年没有牵头血栓性血小板减少性紫癜的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 8 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 30 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
这些数字背后的记录
牵头的论文3
- Predictors for pulmonary artery involvement in Takayasu arteritis and its cluster analysis.
- Analysis of clinical features between active and inactive patients of Takayasu's arteritis with pulmonary arteries involvement.
- Value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of pulmonary artery activity in patients with Takayasu's arteritis.
早期论文(2016–2020 年)3
- Clinical and imaging manifestations of Takayasu's arteritis with pulmonary hypertension: A retrospective cohort study in China.
- [Pulmonary cavities with Takayasu arteritis: report of 3 cases and literature review].
- [The analysis of the clinical records diagnosed as Takayasu's arteritis with pulmonary vascular involvement].
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 12 篇,占 1.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 27 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- 分期
- III期
- 开始
- 2026-09
- 登记号
- NCT07687459
年龄 40 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文12
- Immunological Features and Potential Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis.
- Identifying prothrombin and bone sialoprotein as potential drug targets for idiopathic pulmonary fibrosis.
- Clinical manifestations and prognostic factors analysis of patients hospitalised with acute exacerbation of idiopathic pulmonary fibrosis and other interstitial lung diseases.
- Mendelian randomization analysis suggests no causal influence of gastroesophageal reflux disease on the susceptibility and prognosis of idiopathic pulmonary fibrosis.
- Cluster features in fibrosing interstitial lung disease and associations with prognosis.
- Serum Rcn3 level is a potential diagnostic biomarker for connective tissue disease-associated interstitial lung disease and reflects the severity of pulmonary function.
- MMP19 Variants in Familial and Sporadic Idiopathic Pulmonary Fibrosis.
- Characteristics of Chest HRCT and pulmonary function tests in elderly-onset primary Sjögren syndrome with interstitial lung disease.
- TGFβ1-RCN3-TGFBR1 loop facilitates pulmonary fibrosis by orchestrating fibroblast activation.
- Newly diagnosed non-small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis.
- Air pollution and hospitalization of patients with idiopathic pulmonary fibrosis in Beijing: a time-series study.
- Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.
中文论文(未计入)1
早期论文(2016–2020 年)21
- Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling.
- HYAL1 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits HFL-1 Fibroblast Proliferation When Upregulated.
- Evaluation of health-related quality of life and the related factors in a group of Chinese patients with interstitial lung diseases.
- Mechanical ventilation for acute respiratory failure due to idiopathic pulmonary fibrosis versus connective tissue disease-associated interstitial lung disease: Effectiveness and risk factors for death.
- [Postinflammatroy pulmonary fibrosis of COVID-19: the current status and perspective].
- [A concise review of telomere and telomerase-related genetic markers in fibrotic lung diseases].
- Independent Clinical Factors Relevant to Prognosis of Patients with Idiopathic Pulmonary Fibrosis.
- Clinical features and prognosis of microscopic polyangiitis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis.
- Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone.
- A Rare Missense Variant in Telomerase Reverse Transcriptase is Associated with Idiopathic Pulmonary Fibrosis in a Chinese Han Family.
- Clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia.
- Differentiating Usual Interstitial Pneumonia From Nonspecific Interstitial Pneumonia Using High-resolution Computed Tomography: The "Straight-edge Sign".
- Incidence and radiologic-pathological features of lung cancer in idiopathic pulmonary fibrosis.
- Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
- [Real-life experience with pirfenidone in idiopathic pulmonary fibrosis].
- Increased activated regulatory T cells proportion correlate with the severity of idiopathic pulmonary fibrosis.
- Fibrinolytic system related to pulmonary arterial pressure and lung function of patients with idiopathic pulmonary fibrosis.
- [Clinical features of acute diffuse pulmonary exudative disorders].
- [Differentially expressed genes analysis in expression profile data of pulmonary fibrosis with pulmonary hypertension].
- Phosphatase and tensin homolog deleted on chromosome 10 contributes to phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis via multiple pathways.
- miR-130b-3p Modulates Epithelial-Mesenchymal Crosstalk in Lung Fibrosis by Targeting IGF-1.
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 19 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 24 家医院列在白塞病下全国有 149 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 32 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
牵头的论文4
- Causal relationship between gastroesophageal reflux disease and IgA nephropathy: a Mendelian randomization analysis.
- Efficacy and safety of low-dose corticosteroids combined with leflunomide for progressive IgA nephropathy: a systematic review and meta-analysis.
- Transcriptomic analysis reveals the potential crosstalk genes and immune relationship between IgA nephropathy and periodontitis.
- Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Systematic Review and Meta-Analysis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 16 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
这些数字背后的记录
牵头的论文3
- Non-invasive assessment of esophageal and fundic varices in patients with primary biliary cholangitis.
- Comparative diagnostic efficacy of two-dimensional shear wave and transient elastography in predicting the risk of esophagogastric varices and histological staging in patients with primary biliary cholangitis.
- Association between autoimmune liver diseases and chronic hepatitis B: A multivariable Mendelian randomization study in European population.
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 10 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。
这些数字背后的记录
其他疾病
先天性膈疝
Congenital diaphragmatic hernia2021–2025 年中国大陆作者发表的 60 篇先天性膈疝 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 4 家医院列在先天性膈疝下全国有 46 家医院列在先天性膈疝下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。
其他疾病
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 7 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。
其他相关研究
联系这家医院
出示给工作人员或司机的院名卡
首都医科大学附属北京朝阳医院
Beijing Chao-Yang Hospital
北京
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR Wikidata
Beijing Chaoyang Hospital; Beijing Chao-yang Hospital; Beijing Chaoyang Hospital Affiliated to Capital Medical University; Myeloma Research Center of Beijing Beijing Chao-Yang Hospital; Beijing Chao-yang Hospital Affiliated with Capital Medical University; Beijing Chao-yang Hospital Affiliated to Capital Medical University; Beijing Chaoyang Hospital Capital Medical University; Capital Medical University Beijing Chaoyang Hospital